Articles

Three clinical trials conducted in postmenopausal women with hormone receptor (HR)-positive breast cancer showed no advantage to extending endocrine therapy beyond an initial 5 years. Read More ›

In metastatic hormone receptor (HR)-positive breast cancer, adding everolimus to fulvestrant overcomes resistance to aromatase inhibitor therapy. Read More ›

Updated guidelines for sentinel lymph node biopsy in patients with early-stage breast cancer confirm older conservative guidance. Read More ›

A sophisticated gene signature test has been shown to enhance the prediction of the clinical efficacy of chemotherapy in women with early-stage breast cancer, according to results of the recent phase 3 MINDACT study. The findings will enable many women to safely avoid chemotherapy. Read More ›

A new cyclin-dependent kinase 4/6 inhibitor has received approval as first-line therapy for advanced breast cancer based on impressive results from the randomized, phase 3 MONALEESA-2 study. Read More ›

The Journal of Hematology Oncology Pharmacy is pleased to provide readers the Second Annual Oncology Pharmacy Guide to New FDA Approvals. The goal of this Guide is to offer payers, oncology/hematology pharmacists, and other healthcare stakeholders a comprehensive review of novel oncology/hematology drugs that were approved by the US Food and Drug Administration (FDA) in the previous year. Read More ›

The drugs included in this review were approved by the US Food and Drug Administration (FDA) in 2016. Read More ›

Chronic lymphocytic leukemia (CLL), the most common type of leukemia in adults, is a cancer of B-cell lymphocytes. More than 20,000 Americans will be diagnosed with CLL in 2017, and 4660 patients with die from the disease. Read More ›

In the United States, an estimated 12,310 individuals will be diagnosed with soft-tissue sarcoma in 2016, and 4990 will die of the disease. Read More ›